Noninvasive measurement of tumor heterogeneity in head and neck squamous cell carcinoma
Official title: Noninvasive Intratumor Heterogeneity Evaluation in HNSCC With Multi-omics Insights and Therapeutic Targets
Run by First Affiliated Hospital of Chongqing Medical University · NCT07027280 · Data updated 2026-11-12
This project tests an imaging-based model to see if noninvasive scans can predict treatment response and prognosis for people with head and neck squamous cell carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 15 Years to 89 Years |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | First Affiliated Hospital of Chongqing Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chongqing) |
| Status | Recruiting |
| Started | February 27, 2025 |
| Main results expected | June 15, 2025 |
| Study ends | August 15, 2025 |
| Registry record updated | June 18, 2025 |
| Trial ID | NCT07027280 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with pathologically confirmed head and neck squamous cell carcinoma who have complete preoperative imaging, clinical, and pathological data, available follow-up, and no prior chemotherapy or radiotherapy before surgery.
✕Probably not a fit
Patients who received chemotherapy or radiotherapy before surgery, have poor-quality or too-small tumors on imaging, or have other concurrent malignancies are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study builds an imaging analysis model to quantify intratumoral heterogeneity from patients' preoperative scans. Imaging features will be integrated with clinical, pathological, transcriptomic, and metabolomic data to produce a multi-omics map of tumor heterogeneity. The team will test whether the imaging-derived heterogeneity model can stratify patients by treatment efficacy and prognosis and will use pathology and sequencing to explore underlying mechanisms. Eligible patients must have complete clinical, imaging, and pathological data and must not have received chemotherapy or radiotherapy before surgery.
Why it matters
Potential benefit: If successful, this approach could provide a noninvasive way to personalize treatment choices and better predict outcomes for patients with head and neck cancer.
How similar studies have gone: Radiomics and imaging-based heterogeneity approaches have shown promising predictive results in cancer, but full integration with multi-omics sequencing remains relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Pathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information. Exclusion Criteria: Patients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.
Where it's running
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China Recruiting
Study contacts
- Study coordinator: xinwei Chen
- Email: cxw9977@163.com
- Phone: +8615178870590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
Using Silverlon for head and neck patients with tracheostomies
This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.